Article

Preclinical evaluation of [ <sup>11</sup> C]CHDI-009R for quantification of mutant huntingtin aggregates

2025-06-17

Abstract excerpt

Huntington’s disease (HD) is a neurodegenerative disorder caused by an expanded trinucleotide repeat in the huntingtin gene ( HTT ) that subsequently leads to aggregation of the mutant huntingtin (mHTT) protein. Thus, lowering mHTT is a key therapeutic approach used by several candidate therapeutics currently under investigation. Visualization of the efficiency of these therapeutics through in vivo mHTT quantifi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c05394dc-8ad1-5f9d-8e76-914310e13a0f
DOI: 10.1101/2025.06.17.660088

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Preclinical evaluation of [ <sup>11</sup> C]CHDI-009R for quantification of mutant huntingtin aggregatesDOI 10.1101/2025.06.17.660088Read

Preclinical evaluation of [11C]CHDI-009R for quantification of mutant huntingtin aggregatesSemantic proximity Read

Preclinical evaluation of the novel [ <sup>18</sup> F]CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington’s diseaseSemantic proximity Read

Longitudinal Preclinical Evaluation of the Novel Radioligand [11C]CHDI-626 for PET Imaging of Mutant Huntingtin Aggregates in Huntington’s DiseaseSemantic proximity Read

Preclinical evaluation of the novel [18F]CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington's disease.Semantic proximity Read

In Vivo PET Imaging of [18F]CHDI-385, a Radioligand for Mutant Huntingtin Aggregates in a Mouse Model of Huntington Disease.Semantic proximity Read

PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington's disease.Semantic proximity Read

A novel imaging ligand as a biomarker for mutant huntingtin-lowering in Huntington’s diseaseSemantic proximity Read

Development of a ligand for in vivo imaging of mutant huntingtin in Huntington’s diseaseSemantic proximity Read

In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using11C-CHDI-180R PET in a Nonhuman Primate Model of Huntington DiseaseSemantic proximity Read

Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidatesSemantic proximity Read

Biodistribution and dosimetry of the PET radioligand [18F]CHDI-650 in mice for detection of mutant huntingtin aggregatesSemantic proximity Read

Imaging Mutant Huntingtin Aggregates: Development of a Potential PET Ligand.Semantic proximity Read